Targets for therapy in ependymoma

Targeted Oncology

Volumn 6, Issue 3, 2011, Pages 163-169

  Shonka, Nicole A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Alpha v beta 3; Ependymoma; ErbB2; HER2 neu; Lapatanib; PDGFR alpha

Indexed keywords

CARBOPLATIN; CYCLOOXYGENASE 2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ETOPOSIDE; LAPATINIB; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NERATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR CC; PLATELET DERIVED GROWTH FACTOR DD; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM DERIVATIVE; SOMATOMEDIN; STAT PROTEIN; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ANAPLASTIC CARCINOMA; ANGIOGENESIS; AREA UNDER THE CURVE; AUTOPHOSPHORYLATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CYTOTOXICITY; DIMERIZATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EPENDYMOMA; FOLLOW UP; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN METABOLISM; PROTEIN TARGETING; RADIATION DOSE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; EPENDYMOMA; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; YOUNG ADULT;

EID: 81355122622     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0170-0     Document Type: Review

References (58)

1. CBTRUS (2010) Statistical Report on Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006 Accessed 22 Oct. 2010
2. Poltinnikov IM, Merchant TE (2006) CSF cytology has limited value in the evaluation of patients with ependymoma who have MRI evidence of metastasis. Pediatr Blood Cancer 47(2):169-173 (Pubitemid 44025249)
3. Kawabata Y, Takahashi JA, Arakawa Y, Hashimoto N (2005) Longterm outcome in patients harboring intracranial ependymoma. J Neurosurg 103(1):31-37 (Pubitemid 43193931)
4. WHO Classification of Tumours of the Central Nervous System (2007) World Health Organization Classification of Tumours, 4th edn. International Agency for Research on Cancer, Lyon
5. Hemminki K, Li X, Vaittinen P, Dong C (2000) Cancers in the first-degree relatives of children with brain tumours. Br J Cancer 83(3):407-411 (Pubitemid 30453585)
6. Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR (2010) Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol 12(8):862-870
7. Godfraind C (2009) Classification and controversies in pathology of ependymomas. Childs Nerv Syst 25(10):1185-1193
8. Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, Jouvet A, Guyotat J (2007) Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 130(Pt 5):1338-1349 (Pubitemid 47355950)
9. Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, Salmon I, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C (2007) Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer 6:47
10. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schottler A, Kulozik AE, Witt O, von Deimling A, Lichter P, Pfister S (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28(19):3182-3190
11. Healey EA, Barnes PD, Kupsky WJ, Scott RM, Sallan SE, Black PM, Tarbell NJ (1991) The prognostic significance of postoper-ative residual tumor in ependymoma. Neurosurgery 28(5):666- 671, discussion 671-662
12. Paulino AC, Wen BC, Buatti JM, Hussey DH, Zhen WK, Mayr NA, Menezes AH (2002) Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol 25 (2):117-122 (Pubitemid 34293061)
13. Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, Habrand JL, Doz F, Frappaz D, Gentet JC, Edan C, Chastagner P, Kalifa C (2001) Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19(5):1288-1296 (Pubitemid 32202532)
14. Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR et al (1993) Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328(24):1725-1731 (Pubitemid 23170121)
15. Merchant TE, Mulhern RK, Krasin MJ, Kun LE, Williams T, Li C, Xiong X, Khan RB, Lustig RH, Boop FA, Sanford RA (2004) Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22 (15):3156-3162 (Pubitemid 41103730)
16. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T (2005) Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23(30):7621-7631 (Pubitemid 46291826)
17. Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, Wisoff JH, Milstein JM, Allen JC, Finlay JL et al (1994) Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 12(8):1607-1615 (Pubitemid 24244996)
18. Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, Cox T, Chong WK, Campbell RH, Bailey CC, Gattamaneni R, Picton S, Thorpe N, Mallucci C, English MW, Punt JA, Walker DA, Ellison DW, Machin D (2007) Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8(8):696-705 (Pubitemid 47189085)
19. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R (2008) Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol 10(6):1040-1060
20. Salazar OM, Castro-Vita H, VanHoutte P, Rubin P, Aygun C (1983) Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg 59(4):652-659 (Pubitemid 13008564)
21. Shaw EG, Evans RG, Scheithauer BW, Ilstrup DM, Earle JD (1987) Postoperative radiotherapy of intracranial ependymoma in pediatric and adult patients. Int J Radiat Oncol Biol Phys 13 (10):1457-1462 (Pubitemid 17164165)
22. Schild SE, Nisi K, Scheithauer BW, Wong WW, Lyons MK, Schomberg PJ, Shaw EG (1998) The results of radiotherapy for ependymomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 42(5):953-958 (Pubitemid 29004134)
23. Gilbert MR, Ruda R, Soffietti R (2010) Ependymomas in adults. Curr Neurol Neurosci Rep 10(3):240-247
24. Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F, Magli A, Franzin A, Basso U, Villa E (2004) A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 100(6):1221-1229 (Pubitemid 38325951)
25. Guyotat J, Signorelli F, Desme S, Frappaz D, Madarassy G, Montange MF, Jouvet A, Bret P (2002) Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol 60 (3):255-268 (Pubitemid 35439180)
26. Chamberlain MC, Johnston SK (2009) Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. Cancer 115(20):4775-4782
27. Soffietti R, Costanza A, Laguzzi E, Trevisan E, Ruda R (2005) Temozolomide in rare brain tumors of the adult: a prospective study. J Clin Oncol (Meeting Abstracts) 23(16 suppl):1574
28. Olayioye MA (2001) Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 3(6):385-389 (Pubitemid 34196365)
29. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW (2002) ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8(10):3054-3064 (Pubitemid 35155014)
30. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S,Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15 (4):1452-1459
31. Kuhn J, Robins I, Mehta, M et al (2008) Tumor sequestration of lapatanib (NABTC 04-01) In: Society of Neuro-Oncology, 2008. Neuro Oncol, 795-915
32. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P, Stewart C, Keir ST, Lock R, Carol H, Reynolds CP, Maris JM, Wu J, Smith MA (2009) Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 53(4):594-598
33. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ (2010) Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28(27):4221-4227
34. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68(4):356-366
35. Nait Oumesmar B, Vignais L, Baron-Van Evercooren A (1997) Developmental expression of platelet-derived growth factor alphareceptor in neurons and glial cells of the mouse CNS. J Neurosci 17 (1):125-139 (Pubitemid 27008856)
36. Black P, Carroll R, Glowacka D (1996) Expression of plateletderived growth factor transcripts in medulloblastomas and ependymomas. Pediatr Neurosurg 24(2):74-78 (Pubitemid 26226236)
37. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15 (15):1913-1925 (Pubitemid 32738621)
38. De Bustos C, Smits A, Stromberg B, Collins VP, Nister M, Afink G (2005) A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. J Med Genet 42(1):31-37 (Pubitemid 40187118)
39. Fakhrai N, Neophytou P, Dieckmann K, Nemeth A, Prayer D, Hainfellner J, Marosi C (2004) Recurrent spinal ependymoma showing partial remission under Imatimib. Acta Neurochir (Wien) 146(11):1255-1258 (Pubitemid 39517799)
40. Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69(1):11-25
41. Paulus W, Baur I, Schuppan D, Roggendorf W (1993) Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol 143(1):154-163 (Pubitemid 24058169)
42. Lim M, Guccione S, Haddix T, Sims L, Cheshier S, Chu P, Vogel H, Harsh G (2005) alpha(v)beta(3) Integrin in central nervous system tumors. Hum Pathol 36(6):665-669 (Pubitemid 40922573)
43. Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R (1999) Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol 98(3):240-244 (Pubitemid 29396854)
44. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, Black PM (2000) Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 60(17):4926-4931
45. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF (2001) Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61(11):4375-4381 (Pubitemid 32685762)
46. Hara A, Okayasu I (2004) Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 108(1):43-48 (Pubitemid 38961072)
47. Matsuo M, Yonemitsu N, Zaitsu M, Ishii K, Hamasaki Y, Fukuyama K, Tabuchi K, Miyazaki S (2001) Expression of prostaglandin H synthase-2 in human brain tumors. Acta Neuropathol 102(2):181-187 (Pubitemid 32771667)
48. Kim SK, Lim SY, Wang KC, Kim YY, Chi JG, Choi YL, Shin HJ, Cho BK (2004) Overexpression of cyclooxygenase-2 in childhood ependymomas: role of COX-2 inhibitor in growth and multi-drug resistance in vitro. Oncol Rep 12(2):403-409
49. Roma AA, Prayson RA (2006) Expression of cyclo-oxygenase-2 in ependymal tumors. Neuropathology 26(5):422-428 (Pubitemid 44454412)
50. Couldwell WT, Antel JP, Yong VW (1992) Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31(4):717-724, discussion 724
51. Ramachandran C, Khatib Z, Petkarou A, Fort J, Fonseca HB, Melnick SJ, Escalon E (2004) Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol 67(1-2):19-28 (Pubitemid 38418245)
52. Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH (2010) Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother Pharmacol 66(5):927-933
53. Ben Arush MW, Postovsky S, Goldsher D, el Hasid R, Constantini S (1999) Clinical and radiographic response in three children with recurrent malignant cerebral tumors with high-dose tamoxifen. Pediatr Hematol Oncol 16(3):245-250 (Pubitemid 29205694)
54. Rojas-Marcos I, Calvet D, Janoray P, Delattre JY (2003) Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin. Neurology 61(7):1019-1020 (Pubitemid 37248676)
55. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12 (1):95-103
56. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22(1):133-142 (Pubitemid 41095125)
57. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98 (1):93-99
58. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12(10):1061-1070